Vertex Pharmaceuticals Inc

VRTX

NASDAQ. Currency in USD

283.45 -2.94 ( -1.03% )

Real time prices: September 23

Market Cap.
72.69B
Beta (5Y monthly)
0.45
Price/Earnings
20.47
EPS (TTM)
14.05
Forward Dividend
0.00 (0.00%)
Ex-Dividend Date
Volume
1.35M
1y Target Est.
310.54
Day's Range
279.70
-
285.12
52 Week's Range
176.36
-
305.95

Historical Summary

Performance
EPS growth
Share Buybacks

About Vertex Pharmaceuticals Inc

Sector
Healthcare
Industry
Biotechnology
Website
https://www.vrtx.com
Exchange
NASDAQ (XNAS)
Shares Outstanding
254.25M
Employees
3900
Address
50 Northern Avenue, Boston, MA, United States, 02210
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Latest news

Recession Fears Increasing: Here's the Best Stock to Buy Right Now
Recession Fears Increasing: Here's the Best Stock to Buy Right Now

There's a lot to like about this high-flying stock.
By The Motley Fool - 1 day ago

Vertex Pharmaceuticals (VRTX) Stock Moves -1.01%: What You Should Know
Vertex Pharmaceuticals (VRTX) Stock Moves -1.01%: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $283.45 in the latest trading session, marking a -1.01% move...
By Zacks Investment Research - 1 day ago

Minimum Volatility & Value ETFs for Turbulent Markets
Minimum Volatility & Value ETFs for Turbulent Markets

We discuss how factor ETFs can help investors in the challenging market environment
By Zacks Investment Research - 2 days ago

2 Monster Stocks to Buy Without Any Hesitation
2 Monster Stocks to Buy Without Any Hesitation

Both are likely to continue beating the market by building on their successes in core...
By The Motley Fool - 2 days ago

Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it...
By Zacks Investment Research - 3 days ago

Should You Buy Stocks Right Now?
Should You Buy Stocks Right Now?

The correct answer: It depends.
By The Motley Fool - 5 days ago